$BIAFSep 1, 2026, 12:01 PMAI processed
bioAffinity pushes CyPath Lung toward post-treatment surveillance for lung cancer survivors
AI Summary
BioAffinity announced it is advancing CyPath Lung as a noninvasive surveillance tool for patients after curative-intent treatment, positioning the sputum-based test to complement CT imaging and help triage new or changing pulmonary nodules without immediate invasive procedures. The company cites prior published detection-stage performance (92% sensitivity, 87% specificity, 99% NPV for nodules <20 mm) but explicitly states those data were for detection and that post-treatment surveillance use has not been separately validated; CyPath Lung is marketed as a CLIA Laboratory Developed Test and is not intended as a sole diagnostic.
Positives
- Company is actively advancing CyPath Lung into post-treatment surveillance, a large potential use case among >680,000 U.S. lung cancer survivors
- Published detection-stage performance shows high sensitivity (92%) and very high NPV (99%) for small nodules, which could help rule out malignancy and reduce invasive procedures
- Test is noninvasive and intended to complement CT imaging for triage of new or changing nodules
Negatives
- Surveillance use has not been separately validated; published metrics relate to detection setting only
- CyPath Lung is offered as a Laboratory Developed Test (CLIA LDT) and is not cleared as a standalone diagnostic, leaving regulatory and adoption limitations
- Forward-looking risks noted, including need for additional data to support new use cases and company-level risks (limited operating history, potential listing compliance concerns)